Asia Pacific Live Biotherapeutic Products And Microbiome Cdmo Market Size & Outlook
Asia Pacific live biotherapeutic products and microbiome cdmo market, 2018-2030 (US$M)
Related Markets
Asia Pacific live biotherapeutic products and microbiome cdmo market highlights
- The Asia Pacific live biotherapeutic products and microbiome cdmo market generated a revenue of USD 1.9 million in 2023.
- The market is expected to grow at a CAGR of 48.1% from 2024 to 2030.
- In terms of segment, c.difficle was the largest revenue generating application in 2023.
- C.difficle is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1.9 million |
| Market revenue in 2030 | USD 29.7 million |
| Growth rate | 48.1% (CAGR from 2023 to 2030) |
| Largest segment | C.difficle |
| Fastest growing segment | C.difficle |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
| Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 6.0% of the global live biotherapeutic products and microbiome cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 29.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Live Biotherapeutic Products And Microbiome CDMO Market Scope
Live Biotherapeutic Products And Microbiome CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific live biotherapeutic products and microbiome cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 84.21% in 2023. Horizon Databook has segmented the Asia Pacific live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to be the fastest-growing region for live biotherapeutic products and microbiome CDMO. The high share of the market can be attributed to various factors such as the growing prevalence of IBD & Crohn's disease and rising R&D investment & funding.
Moreover, rising outsourcing and increasing number of clinical trials are among the major factors responsible for the fastest growth of the market in Asia Pacific. The presence of developing countries such as India & China, which are increasingly focusing on CDMO, and innovations in the biotherapeutic space to reduce the burden of various diseases are expected to drive the regional market.
For instance, according to NIH, India ranks 7th globally and is one of the major destinations to conduct clinical trials. In addition, several companies collaborate with the country for new drug development, and a large number of companies utilize contract manufacturers in India. In addition, established companies are making significant investments in R&D and clinical activities in the Asia Pacific region.
Reasons to subscribe to Asia Pacific live biotherapeutic products and microbiome cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific live biotherapeutic products and microbiome cdmo market databook
-
Our clientele includes a mix of live biotherapeutic products and microbiome cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific live biotherapeutic products and microbiome cdmo market size, by country, 2018-2030 (US$M)
Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
